Cart
sales@molnova.com
Ciamexon
CAS No. 75985-31-8
Ciamexon( —— )
Catalog No. M36147 CAS No. 75985-31-8
Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 304 | In Stock |
|
| 10MG | 456 | In Stock |
|
| 25MG | 747 | In Stock |
|
| 50MG | 1004 | In Stock |
|
| 100MG | 1376 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2753 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCiamexon
-
NoteResearch use only, not for human use.
-
Brief DescriptionCiamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.
-
DescriptionCiamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number75985-31-8
-
Formula Weight203.24
-
Molecular FormulaC11H13N3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N1C(C#N)C1)C2=C(OC)N=C(C)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
A2ti-1
A2ti-1 is a highly selective inhibitor of annexin A2/S100A10 heterotetramer (A2t) (IC50: 24 μM) that inhibits ARV-mediated activation of Src and p38 mitogen-activated protein kinase (MAPK).
-
NP-G2-044
NP-G2-044 is an orally active fascin inhibitor, with an IC50 of ~2 μM. It blocks tumor metastasis and increases antitumor immune response.
-
Astragenol
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.
